35.2 Urinary Antispasmodics, Antimuscarinics, and Anticholinergics

Urinary Antispasmodics, Antimuscarinics, and Anticholinergics

Urinary antispasmodics treat overactive bladder (OAB) and related disorders by relaxing the detrusor muscle, which is the smooth muscle responsible for bladder contraction. For patients dealing with urinary urgency, frequency, and incontinence, these drugs can significantly improve quality of life. Understanding how they work, their side effects, and key nursing considerations is essential for safe administration.

Key Features

These medications all target muscarinic receptors on the detrusor muscle. Normally, the neurotransmitter acetylcholine (ACh) binds to these receptors and triggers bladder contraction. Antimuscarinics block that binding, which relaxes the detrusor and produces three main therapeutic effects:

• Reduced involuntary bladder contractions
• Increased bladder capacity
• Decreased urinary frequency and urgency

Common medications in this class:

Oxybutynin and tolterodine also have direct smooth muscle relaxant effects beyond their antimuscarinic action, which contributes to their efficacy but also increases systemic side effects.

Actions, Side Effects, and Contraindications

Actions: All drugs in this class reduce bladder contractions and increase bladder capacity through muscarinic receptor antagonism. The clinical result is fewer episodes of urgency, frequency, and urge incontinence.

Side effects: Because muscarinic receptors exist throughout the body (not just the bladder), anticholinergic side effects are common:

• Dry mouth (most frequently reported)
• Constipation
• Blurred vision
• Drowsiness and confusion (particularly concerning in elderly patients)
• Urinary retention (paradoxically, the drug meant to help the bladder can make it too relaxed to empty)

Newer agents like darifenacin and solifenacin are more selective for the M3 muscarinic receptor subtype found in the bladder, which means fewer systemic side effects compared to older drugs like oxybutynin.

Contraindications:

• Urinary retention or gastric retention
• Uncontrolled narrow-angle glaucoma
• Significant hepatic or renal impairment
• Myasthenia gravis (blocking ACh worsens muscle weakness)
• History of QT prolongation
• Use caution in elderly patients due to increased risk of cognitive impairment, confusion, and falls

Nursing Considerations

1. Assess for contraindications before administering. Check the patient's history for glaucoma, urinary retention, liver/kidney function, and current medications that could prolong the QT interval.
2. Monitor effectiveness by tracking urinary frequency, urgency, and incontinence episodes. A decrease in these symptoms indicates the drug is working.
3. Watch for urinary retention. If the patient reports difficulty voiding or a feeling of incomplete emptying, notify the provider. Measure post-void residual volume if indicated.
4. Monitor anticholinergic burden, especially in elderly patients who may already be on other medications with anticholinergic properties. Cumulative effects raise the risk of confusion, falls, and delirium.
5. Administer with or without food as directed. Some formulations (particularly extended-release) should be swallowed whole and not crushed or chewed.
6. Advise consistent timing. Taking the medication at the same time each day maintains steady therapeutic levels.
7. Caution about sedation. Advise patients to avoid driving or operating machinery until they know how the medication affects them.
8. Reinforce non-pharmacological strategies alongside medication, including pelvic floor exercises (Kegels) and bladder training techniques.

Patient Education Plan

• Purpose of the medication: Explain that the drug relaxes the bladder muscle to reduce urgency, frequency, and incontinence. Set realistic expectations: full effects may take several weeks.
• Managing side effects: Suggest sugar-free candy or gum for dry mouth, increased fiber and fluid intake for constipation, and reporting blurred vision or confusion promptly.
• Do not stop abruptly. Sudden discontinuation can cause rebound symptoms (worsening urgency and frequency). Patients should taper under provider guidance.
• Keep a bladder diary. Tracking fluid intake, voiding times, and incontinence episodes helps both the patient and provider evaluate whether the medication is working.
• Lifestyle modifications that support treatment:
  • Limit caffeine and alcohol (both are bladder irritants)
  • Maintain a healthy weight (excess weight increases abdominal pressure on the bladder)
  • Practice timed voiding rather than waiting for urgency
• Follow-up appointments are important for assessing effectiveness, adjusting doses, and screening for side effects over time.